Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, Hájek R, Liu Z, Minarik J, Moreau P, Romejko-Jarosinska J, Spicka I, Vorobyev VI, Besemer B, Ishida T, Janowski W, Kalayoglu-Besisik S, Parmar G, Robak P, Zamagni E, Goldschmidt H, Martin TG, Manier S, Mohty M, Oprea C, Brégeault MF, Macé S, Berthou C, Bregman D, Klippel Z, Orlowski RZ; IMROZ Study Group. Facon T, et al. Among authors: mace s. N Engl J Med. 2024 Oct 31;391(17):1597-1609. doi: 10.1056/NEJMoa2400712. Epub 2024 Jun 3. N Engl J Med. 2024. PMID: 38832972 Clinical Trial.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Attal M, et al. Among authors: mace s. Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Lancet. 2019. PMID: 31735560 Clinical Trial.
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.
Richardson PG, Perrot A, Miguel JS, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang SY, Minarik J, Cavo M, Prince HM, Macé S, Zhang R, Dubin F, Morisse MC, Anderson KC. Richardson PG, et al. Among authors: mace s. Haematologica. 2024 Jul 1;109(7):2239-2249. doi: 10.3324/haematol.2023.284325. Haematologica. 2024. PMID: 38299578 Free PMC article. Clinical Trial.
A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Quach H, Parmar G, Ocio EM, Prince HM, Oriol A, Crowther H, Tsukada N, Bories P, Madan S, Nathwani N, Sunami K, Semiond D, Yu D, Cordero P, Macé S, Suzan F, Moreau P. Quach H, et al. Among authors: mace s. Haematologica. 2024 Dec 1;109(12):4078-4082. doi: 10.3324/haematol.2023.284730. Haematologica. 2024. PMID: 39157871 Free PMC article. No abstract available.
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.
Richardson PG, Perrot A, Mikhael J, Martin T, Beksac M, Spicka I, Capra M, D'Agostino M, Sonneveld P, Bisht K, Fukao T, Zhang R, Tada K, Tekle C, Macé S, Klippel Z, van de Velde H, Moreau P. Richardson PG, et al. Among authors: mace s. Blood Cancer J. 2024 Nov 28;14(1):209. doi: 10.1038/s41408-024-01149-w. Blood Cancer J. 2024. PMID: 39609425 Free PMC article. Clinical Trial.
Clinical Policy: Use of Thrombolytics for the Management of Acute Ischemic Stroke in the Emergency Department.
American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Thrombolytics; Lo BM, Carpenter CR, Milne K, Panagos P, Haukoos JS, Diercks DB; Members of the American College of Emergency Physicians (ACEP) Clinical Policies Committee (Oversight Committee); Diercks DB, Anderson JD, Byyny R, Carpenter CR, Friedman BW, Gemme SR, Gerardo CJ, Godwin SA, Hatten BW, Haukoos JS, Kaji A, Kwok H, Lo BM, Mace SE, Mattu A, Promes SB, Shah KH, Shih RD, Silvers SM, Slivinski A, Smith MD, Thiessen MEW, Thompson JT, Tomaszewski CA, Trent SA, Valente JH, Westafer LM, Wall SP, Yu Y, Lin MP, Finnell JT, Schulz T, Vandertulip K. American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Thrombolytics, et al. Among authors: mace se. Ann Emerg Med. 2024 Dec;84(6):e57-e86. doi: 10.1016/j.annemergmed.2024.07.023. Ann Emerg Med. 2024. PMID: 39578010 Review. No abstract available.
Clinical Policy: Critical Issues in the Evaluation of Adult Patients Presenting to the Emergency Department With Acute Blunt Trauma.
American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Blunt Trauma; Gerardo CJ, Blanda M, Garg N, Shah KH, Byyny R, Wolf SJ, Diercks DB; Members of the American College of Emergency Physicians Clinical Policies Committee (Oversight Committee); Wolf SJ, Diercks DB, Anderson J, Byyny R, Carpenter CR, Finnell JT, Friedman BW, Gemme SR, Gerardo CJ, Godwin SA, Hahn SA, Hatten BW, Haukoos JS, Kaji A, Kwok H, Lo BM, Mace SE, Moran M, Promes SB, Shah KH, Shih RD, Silvers SM, Slivinski A, Smith MD, Thiessen MEW, Tomaszewski CA, Trent SA, Valente JH, Wall SP, Westafer LM, Yu Y, Cantrill SV, Schulz T, Vandertulip K. American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Blunt Trauma, et al. Among authors: mace se. Ann Emerg Med. 2024 Oct;84(4):e25-e55. doi: 10.1016/j.annemergmed.2024.05.027. Ann Emerg Med. 2024. PMID: 39306386 No abstract available.
285 results